8-K: Globus Medical to Acquire Nevro Corp. in $250 Million All-Cash Deal

Globus Medical will acquire Nevro Corp. for $5.85 per share in an all-cash transaction valued at approximately $250 million, aiming to expand treatment options for patients and enhance market penetration.

Summary

• Globus Medical, Inc. has entered into an agreement to acquire Nevro Corp. in an all-cash transaction.
• Globus Medical will pay $5.85 per share, valuing the deal at approximately $250 million.
• The acquisition aims to expand Globus Medical's presence in neuromodulation and other technologies.
• The transaction is expected to close in the second quarter of 2025, pending shareholder and regulatory approvals.
• Globus Medical expects the acquisition to be accretive to its earnings in the second year of operation.
• Globus Medical reaffirms its 2025 net sales guidance of $2.66 billion to $2.69 billion on a stand-alone basis.
• Following the acquisition, Globus Medical anticipates 2025 net sales of $2.80 billion to $2.90 billion and fully diluted non-GAAP earnings per share range between $3.10 to $3.40.
• Nevro announced preliminary 2024 worldwide revenue of $408 million to $409 million.
• Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year on an as-reported basis.

Sentiment

Score: 8

Explanation: The announcement is positive, indicating growth and expansion for Globus Medical. The acquisition of Nevro is expected to be accretive to earnings, and both companies express optimism about the future.

Positives

• The acquisition will expand Globus Medical's product offerings into neuromodulation and other technologies.
• Globus Medical expects the acquisition to be accretive to its earnings in the second year of operation.
• Nevro's technology will benefit from Globus Medical's scale and operational capabilities.
• The acquisition will allow Nevro to reach more patients globally with its products.

Risks

• The transaction is subject to shareholder and regulatory approvals, and other customary closing conditions.
• The integration of Nevro's business may present risks and costs.
• The ability to achieve anticipated synergies is not guaranteed.
• There are risks associated with managing growth and sustaining profitability.

Future Outlook

Globus Medical anticipates increased net sales and earnings per share in 2025 following the acquisition, with the transaction expected to be accretive to earnings in the second year of operation.

Management Comments

• Dan Scavilla, President and CEO of Globus Medical, stated that the acquisition furthers their mission to become the preeminent musculoskeletal technology company and will bring much needed and clinically superior relief to patients suffering from chronic pain.
• Kevin Thornal, Nevro's CEO and President, believes that joining Globus Medical will allow them to reach more patients globally and become a broader and more diversified leader in the pain management space.

Industry Context

The acquisition reflects a trend of consolidation in the medical device industry, with larger companies seeking to expand their product portfolios and market reach through strategic acquisitions. Globus Medical's move to acquire Nevro aligns with this trend, as it seeks to strengthen its position in the musculoskeletal and pain management markets.

Comparison to Industry Standards

• Globus Medical's acquisition of Nevro is similar to other strategic acquisitions in the medical device industry, such as Medtronic's acquisition of Mazor Robotics and Stryker's acquisition of K2M Group Holdings.
• These acquisitions aim to combine complementary technologies and expand market access.
• The $250 million deal value is within the range of other acquisitions of similar-sized medical device companies.
• The expected accretion to earnings in the second year of operation is a typical target for such acquisitions.

Stakeholder Impact

• Shareholders of Nevro will receive $5.85 per share in cash.
• Patients may benefit from expanded treatment options and improved access to care.
• Employees of Nevro will become part of Globus Medical.
• The combined company may have a stronger competitive position in the market.

Next Steps

• Nevro will hold a special stockholder meeting to obtain approval for the transaction.
• The companies will seek regulatory approval for the transaction.
• Globus Medical will report full financial results for 2024 and provide its updated financial outlook for 2025 during its scheduled earnings announcement on February 20, 2025.
• Nevro expects to report its full-year 2024 financial results on March 4, 2025.
• The companies will work towards closing the transaction late in the second quarter of 2025.

Key Dates

Keywords

Globus Medical, Nevro Corp, acquisition, merger, neuromodulation, musculoskeletal, chronic pain, medical device